Aberrant overactivation of the immune system can give rise to chronic and persistent self-attack, culminating in autoimmune disease. This is currently managed therapeutically using potent immunosuppressive and anti-inflammatory drugs. Class I phosphoinositide 3-kinases (PI3Ks) have been identified as ideal therapeutic targets for autoimmune diseases given their wide-ranging roles in immunological processes. Recent studies into the function of selective PI3K inhibitors in vitro and in vivo have yielded encouraging results, allowing progression into the clinic. Here, we review their recent progress across a range of autoimmune diseases.
|Number of pages||5|
|Journal||Drug Discovery Today|
|Early online date||13 Apr 2014|
|Publication status||Published - Aug 2014|
FingerprintDive into the research topics of 'PI3K inhibitors as potential therapeutics for autoimmune disease'. Together they form a unique fingerprint.
Person: Research & Teaching